Urinary tract infections (UTIs) in women represent a common bacteriological finding, with negligible recent and consistent research on antimicrobial resistance (AMR) in the female population. We designed a retrospective study to observe the incidence of frequent uropathogens and their resistance rates to common antibiotics. We elaborated multicenter research in three different teaching hospitals in Romania, analyzing 13,081 urine samples, of which 1588 met the criteria of inclusion. Escherichia coli (58.37%) was the most frequent Gram-negative uropathogen, presenting high resistance rates to levofloxacin (R = 29.66%), amoxicillin–clavulanic ac. (R = 14.13%), and ceftazidime (R = 6.68%). We found good sensitivity to imipenem and meropenem (both 98.16%), amikacin (S = 96.0%), and fosfomycin (S = 90.39%). The second most prevalent uropathogen was Klebsiella (16.93%), with the highest resistance quota to amoxicillin–clavulanic ac. (R = 28.62%), levofloxacin and nitrofurantoin (both R = 15.61%), and ceftazidime (R = 15.24%), and good sensitivity to imipenem (S = 93.93%), meropenem (S = 91.91%), and amikacin (S = 88.47%). Enterococcus (13.35%) was the most encountered Gram-positive pathogen. It proved the highest resistance to levofloxacin (R = 32.07%), penicillin (R = 32.07%), and ampicillin (R = 14.62%) and good sensitivity to vancomycin (S = 91.98%), fosfomycin (S = 94.4%), and nitrofurantoin (S = 89.15%). Considering the lack of recent and consistent data on this topic, we find our survey a valuable starting research study in this area with high significance for an accurate clinical approach.

α‑Lipoic acid (ALA) is a natural molecule that is inconsistently synthesized by the human body and must be provided from exogenous sources, such as food and dietary supplements. Once absorbed, the oxidized form of ALA is transformed into its reduced form, dihydrolipoic acid (DHLA). ALA/DHLA exert direct and indirect antioxidant, anti‑inflammatory and fine immunomodulatory effects. ALA/DHLA reduce the levels of pro‑inflammatory cytokines (IL‑1β, IL‑6, IL‑8 and IL‑17), while increasing the secretion of anti‑inflammatory cytokines (IL‑10). They also inhibit cyclooxygenase 2, thereby decreasing the secretion of prostaglandin E2 and nitrogen oxide, and reducing the risk of miscarriage in the first trimester of pregnancy. In patients at risk of abortion, administration of ALA from the first trimester has shown efficacy by accelerating subchorionic hematoma resorption, with a significant decrease in the accompanying abdominal pain. ALA has been proven to be efficient in maintaining the length of the cervix and keeping it closed following one episode of premature labor. Preeclampsia is a dysfunction caused by abnormal placentation and an excessive maternal inflammatory response, leading to extreme hypoxia in the placental bed and exaggerated oxidative stress, with release of oxygen free radicals. Oxidative stress plays a key role in the development of preeclampsia and intrauterine growth restriction. The hypothesis of antioxidant supplementation may play an essential part in disease prevention and fetal neuroprotection.

Endometriosis is characterized by alterations of the action and control mechanisms that lead to the development of ectopic endometrial tissue. This study aimed to analyze the molecular profile of ectopic endometrium by evaluating the expression of several biomarkers [estrogen receptor (ER), progesterone receptor (PR), anti-apoptotic protein Bcl-2, and Ki-67 antigen] in relation to the stage of the disease and symptoms. A prospective study over a period of one year, consisting of 14 patients with endometriosis, was performed. All patients received laparoscopic surgical treatment for excision of the lesions and staging of the disease. The expression of the aforementioned biomarkers was assessed in the ectopic endometrial tissue from the excised lesions using immunohistochemistry to determine their expression in the glandular epithelium and stroma. The mean expression of biomarkers in the epithelial and stromal levels did not differ significantly based on disease stage. Epithelial ER expression was significantly positively correlated with stromal ER, epithelial PR, and stromal PR. Stromal ER was significantly positively correlated with epithelial PR and stromal Ki-67. Epithelial Bcl-2 was significantly positively correlated with stromal Bcl-2. Epithelial Ki-67 was significantly positively correlated with stromal Ki-67. Finally, epithelial Bcl-2 expression was significantly positively correlated with the intensity of dyspareunia. The correlation between epithelial Bcl-2 expression and the intensity of dyspareunia highlights a potential molecular link to the severity of symptoms in endometriosis. These results suggest that further exploration of these biomarkers could lead to improved understanding of their clinical implications and more personalized therapies for patients with endometriosis.

Coital urinary incontinence is a frequently underdiagnosed manifestation of female pelvic floor dysfunction, characterized by involuntary urine leakage during sexual activity, particularly during vaginal penetration or orgasm. Although interest in this condition has increased in recent years, it remains insufficiently investigated in clinical practice and is often underreported by patients because of stigma, emotional distress, and the negative impact on intimate relationships and quality of life. Current evidence supports the existence of distinct pathophysiological mechanisms depending on the timing of urinary leakage. Leakage occurring during vaginal penetration is more commonly associated with stress urinary incontinence, urethral hypermobility, and pelvic support defects, whereas orgasm-associated urinary incontinence appears to be more closely related to detrusor overactivity and complex pelvic neurophysiological mechanisms. Hormonal changes associated with the peri- and postmenopausal period may further contribute to symptom progression through alterations in urethral and vaginal trophicity, local vascularization, and pelvic neuromuscular function. Clinical evaluation remains challenging because many affected women do not voluntarily report symptoms due to embarrassment or social stigma, therefore it requires targeted questioning regarding urinary leakage during sexual activity, associated lower urinary tract symptoms, and the impact on female sexual health. Therapeutic management should be individualized and tailored to the predominant underlying mechanisms, including pelvic floor rehabilitation, behavioral interventions, pharmacological treatment, local hormonal therapy, and surgical management of stress urinary incontinence or pelvic support defects. Minimally invasive and regenerative therapies, such as vaginal laser therapy, platelet-rich plasma, cellular therapies, and neuromodulation, represent promising therapeutic approaches. Greater awareness and proactive screening during urogynecological evaluation are essential for improving diagnosis, individualized treatment, sexual health, and overall quality of life in affected women.

Obstetric hemorrhage remains one of the leading causes of maternal morbidity and mortality worldwide despite clinical guidelines and effective interventions. Postpartum hemorrhage is the most common and clinically significant form, yet variability persists across guidelines regarding diagnostic criteria, blood-loss assessment, transfusion thresholds, and escalation strategies. In parallel, gynecologic hemorrhage, particularly acute abnormal uterine bleeding, remains an important cause of morbidity and requires a distinct therapeutic approach. This study was conducted as a structured narrative review informed by systematic search principles. A literature search was performed in PubMed, Scopus, and Web of Science for studies published between January 2020 and January 2026, supplemented by targeted searches of guideline repositories and official organizational websites. The review focused on international guidelines and relevant studies on diagnosis, treatment, transfusion practices, and escalation pathways for obstetric and gynecologic hemorrhage. Of 1,248 records identified, 32 studies were included in the final synthesis. Strong convergence was observed regarding early recognition and administration of uterotonics, particularly oxytocin, as first-line therapy, with early use of tranexamic acid as an adjunct within three hours of birth. Increasing evidence supports protocol-driven care over traditional stepwise escalation. Restrictive transfusion strategies are recommended for stable patients, while clinical status remains the primary determinant in patients with active bleeding. Acute abnormal uterine bleeding management relies on antifibrinolytic and hormonal therapy. Contemporary hemorrhage management is increasingly early, physiology-based, multidisciplinary, and protocolized. Optimal outcomes depend on rapid recognition, prompt first-line treatment, and timely escalation. Integrating principles from gynecologic hemorrhage may further strengthen individualized and etiology-driven care.

Influenza in pregnancy is associated with a higher risk of severe respiratory disease and adverse maternal and perinatal outcomes, particularly later in gestation. This narrative review synthesizes evidence on epidemiology, pathophysiology, placental and fetal consequences, clinical presentation, diagnosis, antiviral management, and vaccination. Pregnancy involves dynamic immune adaptation together with reduced respiratory reserve, increased oxygen consumption, and cardiovascular changes that may amplify the effects of influenza pneumonia. Placental and fetal consequences appear to be mediated predominantly by maternal hypoxemia, fever, systemic inflammation, and hemodynamic disturbance; transplacental viral transmission is rare. Therefore, adverse fetal and neonatal outcomes are more closely linked to the severity and timing of maternal illness, placental dysfunction, and prematurity than to direct fetal infection. Prompt recognition is essential, and antiviral treatment should not await laboratory confirmation when influenza is suspected. Oseltamivir remains the preferred antiviral therapy and should be initiated as early as possible, including in patients presenting after 48 h with progressive or severe disease. Seasonal inactivated or recombinant influenza vaccination is the cornerstone of prevention, protecting both the mother and the infant through transplacental transfer of influenza-specific IgG. This integrated perspective supports vaccination, early diagnosis, and timely treatment to reduce maternal and perinatal risk.